ES2604947T3 - Compuestos de pirazin-2-il-piridin-2-il-amina y pirazin-2-il-pirimidin-4-il-amina y su uso - Google Patents
Compuestos de pirazin-2-il-piridin-2-il-amina y pirazin-2-il-pirimidin-4-il-amina y su uso Download PDFInfo
- Publication number
- ES2604947T3 ES2604947T3 ES08806506.5T ES08806506T ES2604947T3 ES 2604947 T3 ES2604947 T3 ES 2604947T3 ES 08806506 T ES08806506 T ES 08806506T ES 2604947 T3 ES2604947 T3 ES 2604947T3
- Authority
- ES
- Spain
- Prior art keywords
- independently
- saturated aliphatic
- alkyl
- alkylene
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 10
- IXZMTZOSMOHJMU-UHFFFAOYSA-N n-pyrazin-2-ylpyrimidin-4-amine Chemical compound C=1N=CC=NC=1NC1=CC=NC=N1 IXZMTZOSMOHJMU-UHFFFAOYSA-N 0.000 title 1
- GOYIJZBEFGZUSR-UHFFFAOYSA-N n-pyridin-2-ylpyrazin-2-amine Chemical compound C=1N=CC=NC=1NC1=CC=CC=N1 GOYIJZBEFGZUSR-UHFFFAOYSA-N 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract description 30
- 125000002947 alkylene group Chemical group 0.000 abstract description 23
- -1 pyrrolidino, piperidino, piperazino Chemical group 0.000 abstract description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 19
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract description 13
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract description 11
- 125000003118 aryl group Chemical group 0.000 abstract description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 10
- 125000001424 substituent group Chemical group 0.000 abstract description 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 8
- 125000005488 carboaryl group Chemical group 0.000 abstract description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract description 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 239000012453 solvate Substances 0.000 abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 abstract description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 abstract 1
- 101100079135 Arabidopsis thaliana NAC92 gene Proteins 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101000678195 Homo sapiens Alpha-1-acid glycoprotein 1 Proteins 0.000 abstract 1
- 101150065082 NRM1 gene Proteins 0.000 abstract 1
- 101100231811 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HSP150 gene Proteins 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 description 15
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97770007P | 2007-10-05 | 2007-10-05 | |
| GBGB0719644.7A GB0719644D0 (en) | 2007-10-05 | 2007-10-05 | Therapeutic compounds and their use |
| GB0719644 | 2007-10-05 | ||
| US977700P | 2007-10-05 | ||
| PCT/GB2008/003362 WO2009044162A1 (en) | 2007-10-05 | 2008-10-06 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2604947T3 true ES2604947T3 (es) | 2017-03-10 |
Family
ID=38739312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08806506.5T Active ES2604947T3 (es) | 2007-10-05 | 2008-10-06 | Compuestos de pirazin-2-il-piridin-2-il-amina y pirazin-2-il-pirimidin-4-il-amina y su uso |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8058045B2 (https=) |
| EP (1) | EP2197874B1 (https=) |
| JP (1) | JP5511668B2 (https=) |
| AU (1) | AU2008306625B2 (https=) |
| CA (1) | CA2738980C (https=) |
| DK (1) | DK2197874T3 (https=) |
| ES (1) | ES2604947T3 (https=) |
| GB (1) | GB0719644D0 (https=) |
| WO (1) | WO2009044162A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2444695T3 (es) | 2006-06-23 | 2014-02-26 | Alethia Biotherapeutics Inc. | Polinucleótidos y polipéptidos implicados en el cáncer |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2740900C (en) | 2008-11-03 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| EP2361902A4 (en) | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
| AR076024A1 (es) * | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| RU2560729C2 (ru) | 2010-01-11 | 2015-08-20 | АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи | Модуляторы никотиновых ацетилхолиновых рецепторов |
| SI3173427T1 (sl) | 2011-03-31 | 2019-08-30 | ADC Therapeutics SA, | Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| EP2763975B1 (en) * | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| JP6073910B2 (ja) * | 2011-11-09 | 2017-02-01 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用 |
| KR102102239B1 (ko) | 2012-01-09 | 2020-04-21 | 에이디씨 테라퓨틱스 에스에이 | 유방암을 치료하기 위한 방법 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| CN104169275B (zh) * | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| EP2802576B1 (en) * | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| ES2624307T3 (es) * | 2012-05-15 | 2017-07-13 | Cancer Research Technology Ltd | 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo |
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| KR102233252B1 (ko) * | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| BR112015009850A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
| US10323036B2 (en) * | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN110872277B (zh) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
| CN110684083B (zh) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用 |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| EP4298095A4 (en) * | 2021-01-30 | 2025-08-27 | Sperogenix Therapeutics Ltd | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS AND THEIR USES |
| TW202317106A (zh) * | 2021-08-27 | 2023-05-01 | 南韓商柳韓洋行 | 作為egfr抑制劑之取代胺基吡啶化合物 |
| TW202317105A (zh) | 2021-08-27 | 2023-05-01 | 南韓商柳韓洋行 | 作為egfr抑制劑之含六員雜芳基之胺基吡啶化合物 |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US805369A (en) * | 1904-10-14 | 1905-11-21 | David Marshall | Tomato-peeling machine. |
| US807554A (en) * | 1905-05-25 | 1905-12-19 | Francis S Heffernan | Non-refillable bottle. |
| US3032984A (en) * | 1959-05-12 | 1962-05-08 | United Aircraft Corp | Rocket pump starting system |
| US3101444A (en) * | 1959-06-30 | 1963-08-20 | John R Montgomery | Electronic pressure measuring means for internal combustion engines responsive to pressure caused spark gap resistance change |
| US3035065A (en) * | 1959-11-05 | 1962-05-15 | Union Carbide Corp | Isomaleimides and a process for the preparation thereof |
| US3093297A (en) * | 1961-09-25 | 1963-06-11 | New York Air Brake Co | Hydrostatic transmission |
| US5037285A (en) * | 1983-04-13 | 1991-08-06 | American National Can Company | Apparatus for injection molding and injection blow molding multi-layer articles |
| US5011597A (en) * | 1988-10-11 | 1991-04-30 | Canzoneri Anthony S | Single cell vertical static flow flotation unit |
| US5034869A (en) * | 1989-11-28 | 1991-07-23 | Choi Young J | Device for fixing a ceiling lamp to a ceiling |
| US5121126A (en) * | 1991-03-12 | 1992-06-09 | Bell Atlantic Network Services Inc. | Beacon enhanced telecommunications system and method |
| US6039718A (en) * | 1998-01-20 | 2000-03-21 | Bracco Research Usa | Multiple use universal connector |
| JP3809786B2 (ja) * | 2001-10-01 | 2006-08-16 | ソニー株式会社 | カートリッジ |
| ATE369854T1 (de) | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7202244B2 (en) * | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| GB0215775D0 (en) * | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
| GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| WO2005011597A2 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005035541A1 (en) * | 2003-10-07 | 2005-04-21 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
| AU2004279427B2 (en) | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US7691866B2 (en) | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| CA2561831A1 (en) | 2004-04-13 | 2005-12-22 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101213187B (zh) | 2005-06-28 | 2012-06-06 | 塞诺菲-安万特股份有限公司 | 作为rho-激酶抑制剂的异喹啉衍生物 |
| MX2009005964A (es) | 2006-12-27 | 2009-06-15 | Sanofi Aventis | Derivados de isoquinolina sustituidos con cicloalquilamina. |
| EP2727909A1 (en) | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
-
2007
- 2007-10-05 GB GBGB0719644.7A patent/GB0719644D0/en not_active Ceased
-
2008
- 2008-10-06 JP JP2010527532A patent/JP5511668B2/ja active Active
- 2008-10-06 AU AU2008306625A patent/AU2008306625B2/en active Active
- 2008-10-06 US US12/680,891 patent/US8058045B2/en active Active
- 2008-10-06 DK DK08806506.5T patent/DK2197874T3/en active
- 2008-10-06 EP EP08806506.5A patent/EP2197874B1/en active Active
- 2008-10-06 ES ES08806506.5T patent/ES2604947T3/es active Active
- 2008-10-06 CA CA2738980A patent/CA2738980C/en active Active
- 2008-10-06 WO PCT/GB2008/003362 patent/WO2009044162A1/en not_active Ceased
-
2011
- 2011-09-23 US US13/241,887 patent/US8367658B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20100311730A1 (en) | 2010-12-09 |
| EP2197874A1 (en) | 2010-06-23 |
| US8367658B2 (en) | 2013-02-05 |
| CA2738980A1 (en) | 2009-04-09 |
| EP2197874B1 (en) | 2016-08-31 |
| JP2010540610A (ja) | 2010-12-24 |
| JP5511668B2 (ja) | 2014-06-04 |
| US8058045B2 (en) | 2011-11-15 |
| WO2009044162A1 (en) | 2009-04-09 |
| GB0719644D0 (en) | 2007-11-14 |
| AU2008306625B2 (en) | 2014-10-16 |
| CA2738980C (en) | 2015-12-01 |
| US20120040967A1 (en) | 2012-02-16 |
| DK2197874T3 (en) | 2016-12-19 |
| AU2008306625A1 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2604947T3 (es) | Compuestos de pirazin-2-il-piridin-2-il-amina y pirazin-2-il-pirimidin-4-il-amina y su uso | |
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| ES2555982T3 (es) | Inhibidores de la proteína quinasa C y usos de los mismos | |
| JP2024534610A5 (https=) | ||
| PE20241356A1 (es) | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer | |
| CO6190512A2 (es) | Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso | |
| RU2010129910A (ru) | 8-анилиноимидазопиридины и способы их использования | |
| AR014974A1 (es) | Compuestos con actividad sobre receptores muscarinicos, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de unmedicamento | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| RU2013151803A (ru) | Бициклические гетероциклические соединения и их применения в терапии | |
| AU2003217936A1 (en) | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders | |
| AR043051A1 (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR072622A1 (es) | Derivados de imidazo[2,1-b][1,3,4]tiadiazol, composiciones farmaceuticas que los comprenden, metodo para prepararlos, y uso de los mismos para el tratamiento de tumores y otras enfermedades inducidas por quinasas | |
| BR112012020557A2 (pt) | formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio. | |
| RU2013125326A (ru) | Гетероциклические соединения в качестве зондов для визуализации tau-патологии | |
| DE60313634D1 (de) | Piperazinsubstituierte arylbenzodiazepine | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR052948A1 (es) | DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC | |
| AR070535A1 (es) | Compuestos inhibidores de raf y metodos para usarlos | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas |